Read more about a monotherapy treatment option for patients with chronic myeloid leukemia in chronic phase with the T315l mutation. This is intended for US healthcare professionals. https://lnkd.in/eUV7r8C5
Novartis US Medical’s Post
More Relevant Posts
-
Postdoctoral researcher in the Ethics of Palliative Care, Institute of Humanities in Medicine, Lausanne University Hospital & University of Lausanne
Excellent paper on pharmacological treatment of cancer pain and opioid induced nausea and vomiting!
To view or add a comment, sign in
-
Why are subtypes important in acute lymphoblastic leukemia (ALL)? Today’s treatment options include targeted therapies based on subtype. Subtype information also helps predict how this complex disease might progress and respond to treatment. 🔗Learn more: https://amgen.ly/3zsRW5D #WorldALLDay
To view or add a comment, sign in
-
What should be ur diagnosis according to this CBC report as 1; RBC, Hhg & Platelets is decrease. 2 ; while lymphocyte is increased. #cbcblood #bloodreport #cbcreport #bacterialinfection #anemia #Dogdisease
To view or add a comment, sign in
-
Learn the importance of multidisciplinary workup and management of respiratory symptoms and insufficiency in this case study about a patient w renal cell carcinoma by Faiz et al. https://lnkd.in/eGCRykCn #immunotherapy #ICIs #JIPO
To view or add a comment, sign in
-
Science Editor of Hepatoma Research (ISSN: 2394-5079, indexed in ESCI, Scopus, 2023 CiteScore: 3.2, 2023 IF: 1.7) , an international peer-reviewed, gold open access journal of OAE Publishing Inc.
<Editorial>#livercancer #HCC #Meded #chronicliverdisease #HCCscreening #diagnosis #whole-course management 💡 Whole-process management of HCC: before treatment, during treatment, and after treatment. Hepatoma Research "Interpretation of Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 edition)" 🔵 Early screening and diagnosis 🔵 Development of treatment plan 🔵 Safety monitoring 🔵 Follow-up May we expect to hear your opinion on the whole-course management of hepatocellular carcinoma? Full Text for free: https://lnkd.in/ggfppa6c
To view or add a comment, sign in
-
Gain insight into the biological, morphological, and clinical differences between Myelodysplastic Neoplasms (MDS) and Acute Myeloid Leukemia (AML), and why patient-centric, tailored treatment approaches are important for patients with either MDS or AML. Watch this video: http://bit.ly/4eDzQ0u
To view or add a comment, sign in
-
This study analyzed data from five trials to assess the clinical outcomes of metastatic renal cell carcinoma (mRCC) patients who underwent cytoreductive nephrectomy (CN) prior to treatment with immune checkpoint inhibitor (ICI) and anti-angiogenic therapy. Among 981 included patients, those who underwent CN showed significantly longer median progression-free survival (15 vs. 11 months) and overall survival (46 vs. 28 months) compared to those who did not, along with a higher objective response rate (60% vs. 46%). However, the study acknowledges potential biases in patient selection for CN and suggests prospective determination and stratification of CN in future trials to accurately evaluate its impact on prognosis in mRCC. Source: Journal of the NCI https://lnkd.in/d-FiAAsN Jaleh Fallah Haley Gittleman Chana Weinstock Elaine Chang Sundeep Agrawal Paul Kluetz Laleh Amiri
To view or add a comment, sign in
-
Curis is tirelessly developing groundbreaking therapeutics to enhance the lives of patients. Currently, they are conducting a Phase 1/2a study on emavusertib (CA-4948) for Acute Myelogenous Leukemia (AML) and high-risk Myelodysplastic Syndrome (MDS) patients. Phase 2a focuses on cohorts with specific mutations, offering hope to those who have had limited prior treatment. Treatment cycles involve orally administered emavusertib tablets twice daily. Let's spread the word and encourage eligible patients to explore this potential breakthrough. 💙 For more details, consult your healthcare provider or visit ClinicalTrials.gov and search NCT04278768. #MDSFoundation #BloodCancerAwareness #RareCancer #MDSResearch #MDSSupport
To view or add a comment, sign in
-
MSAT Scientist I Personalized Medicine I Ai/ML| hiPSCs stem cells | Analytics & QC | cGMP | Cell & Gene Therapy | CAR-T ♋I CAR-T | ImmunoTherapy | Gene editing CRISPR🧬✂️ #CAR-T🔬🦠🩸🫁🫀|
Absolute lymphocyte count (ALC) Blood test may predict patients responses to CAR T-cell therapy Higher values in test of immune cell numbers linked to better outcomes https://lnkd.in/gd8YYZgz
To view or add a comment, sign in
-
#Chronic Myeloid Leukemia (CML) is one of the rare types of blood cancer, affecting only 1 or 2 out of every 100,000 people worldwide. #CML is a type of cancer that starts in the bone marrow and spreads to the blood, accounting for 15% of #leukemia cases in adults. It is referred to as “chronic” because it generally progresses more slowly and is primarily seen in adults. 🩸🧐 If #CML is not diagnosed and treated early, it can unfortunately develop into a life-threatening condition within 2-3 years. Therefore, #earlydiagnosis and continuous treatment are crucial in managing CML. 🩺👩🏻⚕️ While there have been significant advancements in #CML treatment over the last 20 years, thanks to Novartis’ innovative therapies, there is still an unmet need for patients who develop resistance to treatment. As #Novartis, the leading company to bring #groundbreaking treatments for #blood cancers to patients worldwide, we remain committed to addressing these unmet needs and developing innovative therapies for #blooddiseases. With our patient-centered approach, we are researching the latest treatment methods and working to raise awareness about the importance of treatment adherence and disease management through our awareness projects. 🙌🏻🌟 At #NovartisTürkiye, we play a key role in the fight against blood cancers in Türkiye, with innovative products in the #hematology field. Beyond our innovative #oncology and #hematology treatments, we continue to collaborate with patient associations and healthcare professionals to raise #bloodcancer awareness in society and support the growth of knowledge in this area. ✨🙌🏻 Today, on September 22, #CMLAwarenessDay, I encourage you to join us in raising awareness about blood cancers. By sharing the CML awareness video on your social media accounts with the hashtag #GetInformedAboutCML, you can help more people access this critical information. Together, we can make a meaningful impact in the fight against CML💪🏻😇✨ #Novartis #NovartisTürkiye #CML #KML #CMLAwarenessDay #CMLAwareness #bloodcancers #hematology https://lnkd.in/dBnJg_Er
To view or add a comment, sign in
12,911 followers